comparemela.com

Latest Breaking News On - Uspetinib - Page 1 : comparemela.com

Aptose Reports Results for the Second Quarter 2023

─ CRc Response Rate 50% with Tuspetinib/Venetoclax Doublet in Evaluable Patients ─ ─ CRc 44% in Patients Who Failed Prior Venetoclax ── CRc.

Soult ukpyolsiSouth koreaUnited statesAptose biosciencesSusan pietropaoloAptose biosciences incHanmi pharmaceutical incCorporate communications investor relationsToronto stock exchangeAmerican society of hematologyEuropean school of haematologyExchange commissionResponse rateVenetoclax doubletEvaluable patientsPatients who failed prior venetoclax

Aptose Presents Highlights from Clinical Update

Finalized Dose Escalation/Dose Exploration Trial in 77 R/R AML PatientsFavorable safety with monotherapy responses across four dose levels with no DLT in.

United statesAptose biosciencesSusan pietropaoloAptose biosciences incLifesci advisorsEuropean hematology association in frankfurtExchange commissionInternational congressFinalized doseDose exploration trialEuropean hematology associationChief executiveUnited states securitiesSci advisorsNasdaq aptoAptose biosciences

Aptose Announces Updated Clinical Responses, Breadth of

Company Provides Comprehensive Clinical Update from Phase 1/2 TrialTuspetinib Continues to Deliver Single Agent Responses in r/r AML PatientsTuspetinib.

United statesAmerican society of hematologyCompany provides comprehensive clinicalDepartment of leukemiaHanmi pharmaceutical companyAptose biosciences incMd anderson cancer centerCompany provides comprehensive clinical updateDeliver single agent responsesEfficacy profilePosition drugPreferred kinase inhibitorTriplet combinationMaintenance therapyPatients failedContinuous dosing ongoing

vimarsana © 2020. All Rights Reserved.